<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83626">
  <stage>Registered</stage>
  <submitdate>18/02/2009</submitdate>
  <approvaldate>22/04/2009</approvaldate>
  <actrnumber>ACTRN12609000203257</actrnumber>
  <trial_identification>
    <studytitle>Dose-Finding Study of the Relationship between Oral Vitamin D3 and Serum 25-Hydroxy Vitamin D3 Concentration.  Protocol: ODS25</studytitle>
    <scientifictitle>Dose-Finding Study of the Relationship between Oral Vitamin D3 and Serum 25-Hydroxy (OH) Vitamin D3 Concentration to achieve a target serum 25-OH vitamin D3 concentration in patients attending rheumatology outpatient clinics.  Protocol: ODS25</scientifictitle>
    <utrn />
    <trialacronym>ODS25</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>No health problem. This is a dose finding study with outcomes being serum concentration of 25-OH vitamin D3. There are no clinical outcome measures.</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral vitamin D3 at starting dose of 20,000U per week followed by dose adjustment 6-weekly to achieve a target serum 25-OH vitamin D3 concentration of 140-180 nmol/L. Each participant will be on trial for 12 months, regardless of whether or not they have achieved the target serum 25-OH vitamin D3 levels.</interventions>
    <comparator>Nil-open label single arm dose finding study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome is descriptive. It will document the range of oral vit D3 dose(s) required to achieve a serum concentration of 140-180 nmol/L 25-OH vitamin D3 at two successive 6-weekly measures. The serum 25-OH vitamin D3 will be determined by radioimmunoassay.</outcome>
      <timepoint>The achievement of target concentrations of serum 25-OH vitamin D3 at two successive 6-weekly measures is expected to occur at different times in different participants. However, all participants will continue on-study for 12 months after the initial oral vitamin D3 administration.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>N/A</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients attending rheumatology outpatient clinics, serum 25-hydroxy vitamin D3 &lt; 100 nmol/L</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy and lactation, women of childbearing age not using contraception, history of hypercalcemia or parathyroid disease, chronic renal failure with evidence of renal stones (calculated creatinine clearance must be &gt; 50 ml/min by the Cockcroft-Gault equation), sarcoidosis with hypercalcemia, unsuppressed Pagets disease, metastatic bone disease, calcium pyrophosphate deposition disease (pseudogout), heterogenous calcification</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/03/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Michael James</primarysponsorname>
    <primarysponsoraddress>Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will determine the range of oral doses of vitamin D that are necessary to raise blood levels of vitamin D to an extent that may have positive effects in patients with rheumatoid arthritis. This study will not examine rheumatoid arthritis outcomes, but the results will be used to plan a later study with rheumatoid patients to examine the effects of vitamin D.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital,
North Terrace,
Adelaide
SA 5000</ethicaddress>
      <ethicapprovaldate>25/02/2009</ethicapprovaldate>
      <hrec>090211</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof Les Cleland</name>
      <address>Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>+61-8-82225190</phone>
      <fax />
      <email>les.cleland@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Les Cleland</name>
      <address>Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>+61-8-82225190</phone>
      <fax />
      <email>les.cleland@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof Michael James</name>
      <address>Rheumatology Unit
Royal Adelaide Hospital
North Tce
Adelaide SA 5000</address>
      <phone>+61-8-82225761</phone>
      <fax />
      <email>michael.james@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>